Literature DB >> 19276865

Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors.

Etta Vinik1, Cristi A Carlton, Maria P Silva, Aaron I Vinik.   

Abstract

OBJECTIVE: To develop a disease-specific questionnaire for identifying domains having the greatest impact on the quality of life (QOL) of patients with neuroendocrine tumors (NETS).
METHODS: Patient responses to clinical interviews provided an 80-item initial pool for the development of the QOL-NET. The Delphi panel reviewed the items for content validity; the patient focus group reviewed the items for content/readability. Domains were derived from analysis of224 questionnaire responses. After principal components analysis, a scree plot suggested 7 domains. Exploratory factor analysis with forced 7-factor varimax rotation determined an ideal structure. Reliability/reproducibility was determined by test/retest 4 to 6 weeks apart. Logistic regression determined each domain score.
RESULTS: All 7 domains exhibited strong internal consistency (Cronbach alpha = 0.86-0.97). Physical functioning contributed 40% of the total QOL score, followed by flushing, gastrointestinal symptoms, respiratory, cardiovascular, depression, and attitude domains. Most items loaded 0.40 or higher. No significant differences in test and retest scores. The mean values for the total QOL and 4 of 7 factor scores were significantly higher (P < 0.05) for NETS than controls: sensitivity was 71.4% and specificity was 69.6% to discriminate the NETS from the controls.
CONCLUSIONS: We developed a 7-domain tool to determine QOL in NETS. Strong internal consistency exists within each domain of the QOL-NET. The QOL-NET is reliable and reproducible but weakly identifies NETS. Physical functioning is a greatest contributor to QOL impairment in NETS.

Entities:  

Mesh:

Year:  2009        PMID: 19276865     DOI: 10.1097/MPA.0b013e31819b6441

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  11 in total

1.  Development and Validation of the Norfolk Quality of Life Fatigue Tool (QOL-F): A New Measure of Perception of Fatigue.

Authors:  Etta J Vinik; Aaron I Vinik; Serina A Neumann; Rajan Lamichhane; Steven Morrison; Sheri R Colberg; Ying-Chuen Lai; James Paulson; Richard Handel; Carolina Casellini; Kim Hodges; Joshua Edwards; Henri K Parson
Journal:  J Am Med Dir Assoc       Date:  2019-12-16       Impact factor: 4.669

2.  Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.

Authors:  Aaron Vinik; Andrew Bottomley; Beata Korytowsky; Yung-Jue Bang; Jean-Luc Raoul; Juan W Valle; Peter Metrakos; Dieter Hörsch; Rajiv Mundayat; Arlene Reisman; Zhixiao Wang; Richard C Chao; Eric Raymond
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

3.  Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.

Authors:  Aaron I Vinik; Eric Raymond
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

4.  Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

Authors:  George A Fisher; Edward M Wolin; Nilani Liyanage; Susan Pitman Lowenthal; Beloo Mirakhur; Rodney F Pommier; Montaser Shaheen; Aaron Vinik
Journal:  Oncologist       Date:  2017-10-16

Review 5.  AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids.

Authors:  Eric H Liu; Carmen C Solorzano; Laurence Katznelson; Aaron I Vinik; Richard Wong; Gregory Randolph
Journal:  Endocr Pract       Date:  2015-05       Impact factor: 3.443

6.  Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden.

Authors:  Timothy P Pearman; Jennifer L Beaumont; David Cella; Maureen P Neary; James Yao
Journal:  Support Care Cancer       Date:  2016-03-31       Impact factor: 3.603

Review 7.  Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

Authors:  Ashley Kieran Clift; Mark Kidd; Lisa Bodei; Christos Toumpanakis; Richard P Baum; Kjell Oberg; Irvin M Modlin; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 5.135

8.  Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours.

Authors:  G Yadegarfar; L Friend; L Jones; L M Plum; J Ardill; B Taal; G Larsson; K Jeziorski; D Kwekkeboom; J K Ramage
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

Review 9.  Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review.

Authors:  I Chau; R Casciano; J Willet; X Wang; J C Yao
Journal:  Eur J Cancer Care (Engl)       Date:  2013-07-29       Impact factor: 2.520

Review 10.  Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours.

Authors:  Caroline Martini; Eva-Maria Gamper; Lisa Wintner; Bernhard Nilica; Barbara Sperner-Unterweger; Bernhard Holzner; Irene Virgolini
Journal:  Health Qual Life Outcomes       Date:  2016-09-10       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.